Trial · NCT00769379
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival | Arm I (Standard WBI) | 95.1 | 95% Confidence Interval 93.8 to 96.5 | percentage of patients event free | |
| Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival | Arm II (WBI, Trastuzumab) | 96.1 | 95% Confidence Interval 94.9 to 97.3 | percentage of patients event free | |
| Invasive or DCIS Disease-free Survival | Arm I (Standard WBI) | 88.4 | 95% Confidence Interval 86.3 to 90.4 | percentage of patients event free | |
| Invasive or DCIS Disease-free Survival | Arm II (WBI, Trastuzumab) | 90.6 | 95% Confidence Interval 88.8 to 92.5 | percentage of patients event free | |
| Invasive or DCIS Recurrence-free Interval | Arm I (Standard WBI) | 94.4 | 95% Confidence Interval 92.9 to 95.8 | percentage of patients event free | |
| Invasive or DCIS Recurrence-free Interval | Arm II (WBI, Trastuzumab) | 95.8 | 95% Confidence Interval 94.5 to 97.1 | percentage of patients event free | |
| Invasive Regional or Distant-Free Recurrence | Arm I (Standard WBI) | 99.9 | 95% Confidence Interval 99.7 to 100.0 | percentage of patients event free | |
| Invasive Regional or Distant-Free Recurrence | Arm II (WBI, Trastuzumab) | 99.9 | 95% Confidence Interval 99.7 to 100.0 | percentage of patients event free | |
| Contralateral Breast Cancer (Invasive or DCIS) - Free Survival | Arm I (Standard WBI) | 97.9 | 95% Confidence Interval 97.0 to 98.8 | percentage of patients event free | |
| Contralateral Breast Cancer (Invasive or DCIS) - Free Survival | Arm II (WBI, Trastuzumab) | 98.4 | 95% Confidence Interval 97.6 to 99.2 | percentage of patients event free | |
| Overall Survival | Arm I (Standard WBI) | 98.9 | 95% Confidence Interval 98.2 to 99.5 | percentage of patients surviving | |
| Overall Survival | Arm II (WBI, Trastuzumab) | 99.0 | 95% Confidence Interval 98.3 to 99.6 | percentage of patients surviving | |
| Incidence of Post-treatment Amenorrhea in Women Who Were Premenopausal at the Time of Study Entry Premenopausal at the Time of Study Entry | Arm I (Standard WBI) | 63 | percentage of participants | ||
| Incidence of Post-treatment Amenorrhea in Women Who Were Premenopausal at the Time of Study Entry Premenopausal at the Time of Study Entry | Arm II (WBI, Trastuzumab) | 72 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00769379/results